| Catalog: | C-FC-4227A |
| Product Type: | FCM Antibody |
| Size: | 50 µL/100 µL |
| Reactivity: | Human |
| Specificity: | Human PARK7/DJ-1 |
| Analysis mode: | WB,FCM,ICC/IF,IP |
| Host: | Rabbit |
| Clonality: | Monoclonal |
| Isotype: | IgG |
| Alternate names: | parkinson protein 7 |
| Form: | Liquid |
| Shipping: | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage: | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
| Purification method: | Protein A |
| Conjugation: | Unconjugated |
| Immunogen: | Recombinant Human PARK7 / DJ-1 protein |
| Buffer: | 0.2 μm filtered solution in PBS |
Parkinson's disease locus DJ-1 (PARK7) is a differentially expressed transcript. DJ-1 plays a physiologic role in protection of erythroid cells from oxidant damage, a function unmasked in the context of oxidative stress. PARK7 belongs to the peptidase C56 family of proteins. It acts as a positive regulator of androgen receptor-dependent transcription. It may also function as a redox-sensitive chaperone, as a sensor for oxidative stress, and it apparently protects neurons against oxidative stress and cell death. Mutations in the DJ-1 gene are associated with rare forms of autosomal recessive early-onset Parkinson's disease (PD). DJ-1/p53 interactions contribute to apoptosis resistance in clonal myeloid cells and may serve as a prognostic marker in patients with myelodysplastic syndromes (MDS). DJ-1 regulates redox signaling kinase pathways and acts as a transcriptional regulator of antioxidative gene batteries. Therefore, DJ-1 is an important redox-reactive signaling intermediate controlling oxidative stress after ischemia, upon neuroinflammation, and during age-related neurodegenerative processes. Augmenting DJ-1 activity might provide novel approaches to treating chronic neurodegenerative illnesses such as Parkinson's disease and acute damage such as stroke.
Copyright © 2025 Creative Biogene. All rights reserved.